KRAS and metastatic colorectal cancer: Considering that KRAS codon 61 and 146 mutations may also confer resistance to EGFR inhibitors[26-29,93], patients who have metastatic colorectal cancer with KRAS mutation in codon 61 or 146 could receive more tailored management through clinical testing of these additional KRAS codons.